The content on this site is intended for healthcare professionals only
Prof Swanton talks to ecancertv at the EIKCS conference about his work looking at intratumour heterogeneity in renal and lung cancer.
'Intratumour heterogeneity' refers to the subpopulations of cells with distinct genomic alterations within the same solid tumour and its discovery is likely to have implications for cancer therapeutics and biomarkers.
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
